许彪

职  务:

职  称:副教授、硕士生导师

电子邮箱:xb@lzu.edu.cn

科研方向:生物活性肽与疼痛、光药理学

许彪,男,汉族,永利集团3044am官方入口副教授,硕士生导师。20206月毕业于永利集团3044am官方入口生物化学与分子生物学专业,获理学博士学位。20209月至20232月在永利集团3044am官方入口从事“萃英博士后”研究。20232月起受聘为永利集团3044am官方入口医学生理与心理学教研室副教授。

  近年来,主要利用动物行为学、细 胞生物学、分子生物学和电生理学等实验策略,聚焦生物活性肽与疼痛领域的研究。目前主持包括国家自然科学基金和甘肃省自然科学基金在内的科研项目5项,发表学术论文27篇,其中部分工作以第一作者(含共同)发表在Br J Pharmacol、Neuropharmacology、Anesth Analg和J Pain等国际知名期刊,申请国家发明专利5项,国际专利PCT和美国专利各1项。  

 

荣誉称号及奖励

2023年,第二十届全国神经精神药理学学术会议优胜墙报(中国药理学会神经精神药理专业委员会);

2023年,第九届全国大学生基础医学创新研究暨实验设计大赛区赛三等奖(指导老师);

2021年,第一届全国博士后创新创业大赛创新赛优胜奖(中华人民共和国人力资源和社会保障部);

2021年,甘肃省“百千万”创业引领工程暨首届博士后创新创业大赛三等奖(甘肃省人力资源与社会保障厅)

2021年,第十六届张锡均基金全国青年优秀生理学学术论文优秀奖(中国生理学会)

2021年,第十九届全国神经精神药理学学术会议青年学术推广优胜奖(中国药理学会神经精神药理专业委员会);

学术兼职

Eur J PharmacolNeuropeptides学术期刊评审人。

生物活性肽与疼痛(Bioactive Peptides and Pain

针对现有镇痛药物疗效不佳和副作用大的科学问题,基于天然活性肽或阿片肽结构骨架开发全新的药物分子,以期达到高效、低副作用的镇痛效果,最终获得具有潜在应用前景的镇痛药物。

光药理学(Optopharmacology

通过构建光敏感药物分子,从而对特定受体、信号通路、神经活动或生理过程进行精准操控和解析,为阐明药物的药理学机制和疾病的病理学机制提供实验支撑和理论支持。

代表性论文:

  1. Biao Xu, Qinqin Zhang, Dan Chen, Mengna Zhang, Run Zhang, Weidong Zhao, Yu Qiu, Kangtai Xu, Jian Xiao, Jiandong Niu, Yonghang Shi, Ning Li, Quan Fang*. OCP002, a Mixed Agonist of Opioid and Cannabinoid Receptors, Produces Potent Antinociception With Minimized Side Effects. Anesth Analg, 2023, 136: 373-386.
  2. Biao Xu, Run Zhang, Mengna Zhang, Dan Chen, Qinqin Zhang, Nan Zhang, Yonghang Shi, Xuanran Hu, Ning Li, Quan Fang*. NaV1.7 Channel Blocker [Ala5, Phe6, Leu26, Arg28]GpTx-1 Attenuates CFA-induced Inflammatory Hypersensitivity in Rats via Endogenous Enkephalin Mechanism. J Pain, 2023, 24: 840-859.
  3. Biao Xu, Mengna Zhang, Xuerui Shi, Run Zhang, Dan Chen, Yong Chen, Zilong Wang, Yu Qiu, Ting Zhang, Kangtai Xu, Xiaoyu Zhang, Wolfgang Liedtke*, Rui Wang*, Quan Fang*. The multifunctional peptide DN-9 produced peripherally acting antinociception in inflammatory and neuropathic pain via μ- and κ-opioid receptors. Br J Pharmacol, 2020, 177: 93-109.
  4. Biao Xu, Jian Xiao, Kangtai Xu, Qinqin Zhang, Dan Chen, Run Zhang, Mengna Zhang, Hanwen Zhu, Jiandong Niu, Ting Zheng, Ning Li, Xiaoyu Zhang, Quan Fang*. VF-13, a chimeric peptide of VD-hemopressin(α) and neuropeptide VF, produces potent antinociception with reduced cannabinoidrelated side effects. Neuropharmacology, 2020, 175: 108178.
  5. Biao Xu, Yuanyuan Guo, Mengna Zhang, Run Zhang, Dan Chen, Qinqin Zhang, Jian Xiao, Kangtai Xu, Ning Li, Yu Qiu, Hanwen Zhu, Jiandong Niu, Xiaoyu Zhang*, Quan Fang*. Central and peripheral modulation of gastrointestinal transit in mice by DN-9, a multifunctional opioid/NPFF receptor agonist. Neurogastroenterol Motil, 2020, 32: e13848.
  6. Chao Chen#, Biao Xu#, Xuerui Shi, Mengna Zhang, Qinqin Zhang, Ting Zhang, Weidong Zhao, Run Zhang, Zilong Wang, Ning Li, Quan Fang*. GpTx-1 and [Ala5, Phe6, Leu26, Arg28]GpTx-1, two peptide NaV1.7 inhibitors: analgesic and tolerance properties at the spinal level. Br J Pharmacol, 2018, 175: 3911-3927#并列一作).
  7. Run Zhang, Biao Xu, Nan Zhang, Jiandong Niu, Mengna Zhang, Qinqin Zhang, Dan Chen, Yonghang Shi, Danni Chen, Kedi Liu, Xiaodi Zhang, Ning Li, Quan Fang*. Spinal microglia-derived TNF promotes the astrocytic JNK/CXCL1 pathway activation in a mouse model of burn pain. Brain Behav Immun, 2022, 102: 23-39.
  8. Mengna Zhang, Biao Xu, Ning Li, Run Zhang, Qinqin Zhang, Dan Chen, Syed Faheem Askari Rizvi, Kangtai Xu, Yonghang Shi, Bowen Yu, Quan Fang*. OFP011 Cyclic Peptide as a Multifunctional Agonist for Opioid/Neuropeptide FF Receptors with Improved Blood-Brain Barrier Penetration. ACS Chem Neurosci, 2022, 13: 3078-3092.
  9. Mengna Zhang, Biao Xu, Ning Li, Run Zhang, Qinqin Zhang, Xuerui Shi, Kangtai Xu, Jian Xiao, Dan Chen, Jiandong Niu, Yonghang Shi, Quan Fang*. Development of Multifunctional and Orally Active Cyclic Peptide Agonists of Opioid/Neuropeptide FF Receptors that Produce Potent, Long-Lasting, and Peripherally Restricted Antinociception with Diminished Side Effects. J Med Chem, 2021, 64: 13394-13409.
  10. Zilong Wang, Biao Xu, Changyu Jiang, Ting Zhang, Mengna Zhang, Ning Li, Qinqin Zhang, Kangtai Xu, Dan Chen, Jian Xiao, Quan Fang*. Spinal DN-9, a Peptidic Multifunctional Opioid/Neuropeptide FF Agonist Produced Potent Nontolerance Forming Analgesia With Limited Side Effects. J Pain, 2020, 21: 477-493.
  11. Mengna Zhang, Biao Xu, Ning Li, Hui Liu, Xuerui Shi, Qinqin Zhang, Yanbin Shi, Kangtai Xu, Jian Xiao, Dan Chen, Hanwen Zhu, Yulong Sun, Ting Zhang, Run Zhang, Quan Fang*. Synthesis and Biological Characterization of Cyclic Disulfide-Containing Peptide Analogs of the Multifunctional Opioid/Neuropeptide FF Receptor Agonists That Produce Long-Lasting and Nontolerant Antinociception. J Med Chem, 2020, 63: 15709-15725.
  12. Run Zhang, Biao Xu, Qinqin Zhang, Dan Chen, Mengna Zhang, Guanghai Zhao, Kangtai Xu, Jian Xiao, Hanwen Zhu, Jiandong Niu, Ning Li, Quan Fang*. Spinal administration of the multi-functional opioid/neuropeptide FF agonist BN-9 produced potent antinociception without development of tolerance and opioid-induced hyperalgesia. Eur J Pharmacol, 2020, 880: 173169.
  13. Run Zhang, Biao Xu, Mengna Zhang, Ting Zhang, Zilong Wang, Geng Zhao, Guanghai Zhao, Ning Li, Quan Fang*. Peripheral and central sites of action for anti-allodynic activity induced by the bifunctional opioid/NPFF receptors agonist BN-9 in inflammatory pain model. Eur J Pharmacol, 2017, 813: 122-129.
  14. Jian Xiao, Jiandong Niu, Biao Xu, Run Zhang, Mengna Zhang, Nan Zhang, Kangtai Xu, Qinqin Zhang, Dan Chen, Yonghang Shi, Quan Fang*, Ning Li*. NOP01, a NOP receptor agonist, produced potent and peripherally restricted antinociception in a formalin-induced mouse orofacial pain model. Neuropeptides, 2022, 91: 102212.
  15. Ting Zhang, Run Zhang, Biao Xu, Mengna Zhang, Qinqin Zhang, Ning Li, Yu Qiu, Dan Chen, Kangtai Xu, Jian Xiao, Nan Zhang, Quan Fang*, Ning Li*. Spinal endomorphins attenuate burn-injury pain in male mice by inhibiting p38 MAPK signaling pathway through the mu-opioid receptor. Eur J Pharmacol, 2021, 903: 174139.
  16. Ning Li, Zhenglan Han, Biao Xu, Mengna Zhang, Ting Zhang, Xuerui Shi, Weidong Zhao, Yuanyuan Guo, Qinqin Zhang, Quan Fang*. Systemic administration of the bifunctional opioid/neuropeptide FF receptors agonist BN-9 produced peripheral antinociception in preclinical mouse models of pain. Eur J Pharmacol, 2018, 837: 53-63.

 

代表性专利成果:

  1. 方泉;许彪;张梦娜;张润;李宁,一类基于阿片肽和大麻肽的双功能肽及其制备方法与应用,2023-8-4,国家发明专利,ZL202110211993.7。
  2. 方泉;许彪;张梦娜;张润;李宁,一种基于大麻肽(r)VD-Hpα和神经肽FF的嵌合肽及其制备方法与应用,2021-7-27,国家发明专利,ZL201911323745.0。
  3. 方泉;张梦娜许彪张润李宁一类阿片/神经肽FF受体多靶点环肽分子及其制备和应用2021-3-12,国家发明专利,202110272260.4
  4. 方泉;张梦娜王锐许彪石学睿一类阿片和神经肽FF受体多靶点分子BN-9的类似物及其制备方法与应用,2020-5-8,国家发明专利,ZL201810950987.1
  5. 方泉;张梦娜王锐许彪石学睿一类阿片和神经肽FF受体多靶点分子BN-9的二硫键环化类似物及其制备方法和应用,2020-7-31,国家发明专利,ZL201810932993.4
  6. 王锐;方泉王子龙许彪一类阿片和神经肽FF受体的多靶点肽类分子及其制备方法和应用2017-4-13,国际专利PCTPCT/CN2017/080350
  7. Rui Wang; Quan Fang; Zilong Wang; Biao Xu, MULTI-TARGET PEPTIDE MOLECULES OF OPIOID AND NEUROPEPTIDE FF RECEPTOR, PREPARATION FOR MOLECULES, AND APPLICATIONS THEREOF, 2021-11-9, 美国专利,US 11,167,006 B2

主持的科研项目:

  1. 国家自然科学基金青年项目(82301392),2024-2026(在研);
  2. “双一流”引导专项-队伍建设经费-科研启动费(在研);
  3. 甘肃省自然科学基金青年项目(22JR5RA545),2022-2024(在研);
  4. 横向课题PZM21衍生肽的体外活性筛选和镇痛药效评价2022-2025(在研);
  5. 中央高校基本科研业务费博士后创新项目(lzujbky-2021-pd052020-2022(结题)。